PolyPeptide Group AG (CH:PPGN)
:PPGN
PPGN Stock Chart & Stats
CHF29.80
CHF1.30(6.77%)
At close: 4:00 PM EST
CHF29.80
CHF1.30(6.77%)
Day’s Range― - ―
52-Week RangeCHF13.98 - CHF32.70
Previous CloseN/A
Volume22.87K
Average Volume (3M)34.07K
Market Cap
CHF1.05B
Enterprise ValueCHF1.18B
Total Cash (Recent Filing)CHF74.53M
Total Debt (Recent Filing)CHF130.46M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 13, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio-5.12
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF39.67Price Target Upside33.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.69
Revenue Forecast (FY)CHF482.13M
Bulls Say, Bears Say
Bulls Say
Specialized Peptide CDMOPolyPeptide’s narrow, technical focus on peptide APIs and end-to-end CDMO services creates durable competitive advantages: specialized process know‑how, regulatory experience and integrated development-to-commercial scale capabilities raise switching costs and support recurring commercial manufacturing revenue once customers advance to approval.
Steady Revenue GrowthConsistent top-line growth (including +6.2% in 2025) indicates sustained demand for peptide services and supports capacity utilization and scale. Multi-year revenue expansion improves visibility into future commercial volumes and strengthens bargaining power with customers for longer-term supply contracts.
Improving Operating Cash FlowStronger operating cash flow despite accounting losses signals solid cash generation from core CDMO operations. Durable OCF supports funding of working capital and strategic capacity investments internally, reducing reliance on external financing for operating needs over the medium term.
Bears Say
Persistent Net LossesSustained net losses erode retained earnings and constrain internal funding for growth or margin-improving initiatives. Continued negative net income increases dependence on external capital, limits flexibility on pricing or investment, and prolongs the timeline to earn sustained returns on invested capital.
Negative Free Cash Flow In 2025A sharp swing to negative free cash flow reflects heavier capex or working‑capital absorption and reduces cash available after investments. This weakens the company’s ability to self-fund capacity expansion or absorb demand swings without raising external financing, increasing medium-term funding risk.
Rising Leverage And Equity ErosionAn increase in leverage alongside declining equity raises financial risk and interest exposure. Higher debt-to-equity ratios limit flexibility, can raise borrowing costs or covenant sensitivity, and reduce the firm’s buffer to absorb operational setbacks as it seeks to transition back to sustainable profitability.
PolyPeptide Group AG News
PPGN FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was CHF13.98 and its highest was CHF32.70 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF1.05B.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Aug 13, 2026 which is in 123 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Mar 12, 2026. The company reported CHF0.152 earnings per share for the quarter, missing the consensus estimate of CHF0.268 by -CHF0.116.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Undervalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of N/A. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is -0.31.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of CHF0.152 in its last earnings report, missing expectations of CHF0.268. Following the earnings report the stock price went up 8.776%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in CH:PPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
PPGN Stock 12 Month Forecast
Average Price Target
CHF39.67
▲(33.11% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Galderma Group AG
―
Options Prices
Currently, No data available
---